Sartorius Stedim Biotech Stock
Stocks
DIM
FR0013154002
Medical Equipment, Supplies & Distribution
OTC Markets Traded|
Real-time
Euronext Paris
19:35:26 30/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 212.80 EUR | -2.03% |
|
+3.50% | +1.33% |
| 05:35pm | Sartorius Stedim Biotech : Receives a Buy rating from Barclays | ZD |
| 09-28 | Sartorius in demand - analysts optimistic ahead of quarterly results | DP |
| Market Cap | 21.13B 23.95B 19.99B 18.13B 34B 2,298B 34.33B 240B 92.45B 1,173B 89.92B 87.96B 3,776B | P/E 2026 * |
55.7x | P/E 2027 * | 43x |
|---|---|---|---|---|---|
| Enterprise Value | 23.14B 26.22B 21.9B 19.86B 37.23B 2,516B 37.6B 263B 101B 1,285B 98.47B 96.33B 4,135B | EV / Sales 2026 * |
7.4x | EV / Sales 2027 * | 6.6x |
| Free-Float |
28.47% | Yield 2026 * |
0.38% | Yield 2027 * | 0.46% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| DIM | Real-time | |
CBOE
| DIMp | Real-time | |
|
OTC Markets
| SDMHF | Delayed | |
|
Börse Stuttgart
| 56S1 | Delayed | |
|
Tradegate
| 56S1 | Real-time | |
|
Xetra
| 56S1 | Delayed | |
|
Boerse Muenchen
| 56S1 | Real-time | |
|
Deutsche Boerse AG
| 56S1 | Delayed | |
|
London S.E.
| 0NK7 | Delayed | |
|
CBOE
| 0NK7 | Real-time | |
|
Borsa Italiana
| 4DIM | End-of-day quote | |
|
Wiener Boerse
| DIM | End-of-day quote |
Last Transcript: Sartorius Stedim Biotech
| 1 day | -1.66% | ||
| 1 week | +3.89% | ||
| Current month | +8.98% | ||
| 1 month | +8.98% | ||
| 3 months | +17.62% | ||
| 6 months | +25.50% | ||
| Current year | +1.71% |
| 1 week | 205 |  | 221.6 |
| 1 month | 182.4 | | 221.6 |
| Current year | 150 | | 224 |
| 1 year | 150 | | 224 |
| 3 years | 139.1 | | 281 |
| 5 years | 139.1 | | 544 |
| 10 years | 50.13 | | 551 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 51 | 28/03/2023 |
| Chief Tech/Sci/R&D Officer | 61 | 08/09/2011 | |
Petra Müller
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 07/04/2015 | |
Susan Dexter
BRD | Director/Board Member | 69 | 07/04/2015 |
Lothar Kappich
BRD | Director/Board Member | 69 | 14/09/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 17/12/25 | Sell | Company | 750,000 | 0.7706% | ||
| 16/02/24 | Buy | Chief Executive Officer | 1,716,739 | 1.8624% | ||
| 02/03/22 | Sell | Company | 200,442 | 0.2174% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.66% | +3.89% | +24.15% | -4.81% | 23.95B | |
| -1.29% | -3.94% | -25.78% | +3.84% | 175B | |
| -0.36% | -3.27% | -9.30% | +11.07% | 111B | |
| -0.98% | +0.42% | -25.73% | +0.26% | 107B | |
| +0.97% | -2.70% | -47.14% | -10.85% | 75.31B | |
| -1.37% | -3.99% | -4.07% | +67.42% | 58.7B | |
| -0.82% | -1.53% | -3.97% | -30.27% | 49.57B | |
| +1.53% | +1.90% | +15.16% | +55.54% | 49.27B | |
| -1.61% | +0.45% | -17.93% | +21.67% | 42.02B | |
| -0.67% | -2.41% | +27.24% | -9.44% | 32.69B | |
| Average | -0.65% | -0.10% | -6.74% | +10.44% | 72.45B | |
| Weighted average by Cap. | -0.67% | -0.92% | -14.93% | +9.38% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.13B 3.54B 2.96B 2.68B 5.03B 340B 5.08B 35.49B 13.68B 174B 13.3B 13.01B 559B | 3.47B 3.93B 3.28B 2.98B 5.58B 377B 5.64B 39.39B 15.18B 193B 14.77B 14.44B 620B |
| Net income | 377M 427M 357M 323M 606M 40.99B 612M 4.28B 1.65B 20.93B 1.6B 1.57B 67.36B | 481M 545M 455M 413M 774M 52.32B 782M 5.46B 2.11B 26.72B 2.05B 2B 85.98B |
| Net Debt | 2.01B 2.28B 1.9B 1.73B 3.23B 219B 3.27B 22.82B 8.79B 112B 8.55B 8.37B 359B | 1.76B 2B 1.67B 1.51B 2.84B 192B 2.87B 20.02B 7.72B 97.94B 7.51B 7.34B 315B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/09/26 | €212.80 | -2.03% | 159,882 |
| 29/09/26 | €217.20 | +0.28% | 109,142 |
| 28/09/26 | €216.60 | +1.98% | 90,637 |
| 25/09/26 | €212.40 | -1.58% | 89,707 |
| 24/09/26 | €215.80 | +4.96% | 119,204 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DIM Stock
Select your edition
All financial news and data tailored to specific country editions
